📣 VC round data is live. Check it out!

Takara Bio Valuation Multiples

Discover Takara Bio's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Anhui Huaheng, Biotest, CryoPort, SEEGENE and more.

Takara Bio Overview

About Takara Bio

Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.


Founded

2002

HQ

Japan

Employees

1.5K

Financials (LTM)

Revenue: $255M
Net Income: ($61M)

EV

$804M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Takara Bio Financials

Takara Bio reported last 12-month revenue of $255M.

In the same LTM period, Takara Bio generated $128M in gross profit and had net loss of ($61M).

Revenue (LTM)


Takara Bio P&L

In the most recent fiscal year, Takara Bio reported revenue of $283M and EBITDA of $41M.

Takara Bio is profitable as of last fiscal year, with gross margin of 58%, EBITDA margin of 14%, and net margin of 2%.

See analyst estimates for Takara Bio
LTMLast FY202320242025202620272028
Revenue$255M$283M$327M$280M$262M
Gross Profit$128M$164M$197M$165M$137M
Gross Margin50%58%60%59%52%
EBITDA-$41M$78M$43M$41M
EBITDA Margin-14%24%15%16%
EBIT Margin(12%)5%14%5%(7%)
Net Profit($61M)$7M$32M$7M($44M)
Net Margin(24%)2%10%3%(17%)

Financial data powered by Morningstar, Inc.

Takara Bio Stock Performance

Takara Bio has current market cap of $864M, and enterprise value of $804M.

Market Cap Evolution


Takara Bio's stock price is $7.17.

Takara Bio share price increased by 0.1% in the last 30 days, and by 41.8% in the last year.

Takara Bio has an EPS (earnings per share) of $0.05.

See more trading valuation data for Takara Bio
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$804M$864M0.1%0.1%-0.8%41.8%$0.05

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Takara Bio Valuation Multiples

Takara Bio trades at 3.2x EV/Revenue multiple, and 19.7x EV/EBITDA.

See NTM and 2027E valuation multiples for Takara Bio

EV / Revenue (LTM)


Takara Bio Financial Valuation Multiples

As of June 2, 2026, Takara Bio has market cap of $864M and EV of $804M.

Takara Bio has a P/E ratio of (14.2x).

LTMLast FY202320242025202620272028
EV/Revenue3.2x2.8x2.5x2.9x3.1x
EV/EBITDA-19.7x10.3x18.7x19.7x
EV/EBIT(27.1x)56.6x17.3x52.3x(43.1x)
EV/Gross Profit6.3x4.9x4.1x4.9x5.9x
P/E(14.2x)132.2x26.9x119.6x(19.7x)
EV/FCF-(28.9x)(207.7x)(21.0x)(28.9x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Takara Bio Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Takara Bio Margins & Growth Rates

Takara Bio decreased revenue by 10% and net profit by 1029% in the last fiscal year.

In the most recent fiscal year, Takara Bio reported gross margin of 58%, EBITDA margin of 14%, and net margin of 2%.

See estimated margins and future growth rates for Takara Bio

Takara Bio Margins

Last FY202420252026202720282029
Gross Margin58%59%52%50%
EBITDA Margin14%15%16%-
EBIT Margin5%5%(7%)(12%)
Net Margin2%3%(17%)(24%)
FCF Margin(10%)(14%)(11%)-

Takara Bio Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(10%)(14%)(7%)(3%)
Gross Profit Growth(22%)(16%)(17%)(6%)
EBITDA Growth-(45%)(5%)-
EBIT Growth(308%)(67%)(221%)59%
Net Profit Growth(1029%)(77%)(708%)38%
FCF Growth-891%(27%)-

Data powered by FactSet, Inc. and Morningstar, Inc.

Takara Bio Operational KPIs

Takara Bio's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Access forward-looking KPIs for Takara Bio
LTMLast FY202320242025202620272028
Revenue per Employee-$0.2M---
Opex per Employee-$0.1M---
R&D Expenses to Revenue17%15%16%16%16%
Opex to Revenue-53%46%53%57%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Takara Bio Competitors

Takara Bio competitors include Anhui Huaheng, Biotest, CryoPort, SEEGENE, SunOpta, Absci, Gujarat State Fertilizers, Bide Pharmatech Co, Grupa Azoty and Suzhou Sepax Technologies.

Most Takara Bio public comparables operate across Bioindustrials, Life Sciences Tools, AgriTech, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Anhui Huaheng2.7x2.6x18.7x14.6x
Biotest----
CryoPort3.8x3.7x(322.9x)(211.8x)
SEEGENE1.8x1.8x7.0x7.2x
SunOpta-1.4x-12.0x
Absci319.4x196.7x(8.7x)(8.0x)
Gujarat State Fertilizers0.5x-4.8x-
Bide Pharmatech Co2.7x2.5x15.5x-

This data is available for Pro users. Sign up to see all Takara Bio competitors and their valuation data.

Start Free Trial

Acquisitions by Takara Bio

Takara Bio has acquired 3 companies to date.

Last acquisition by Takara Bio was on January 15th 2025. Takara Bio acquired Curio Bioscience for $6B (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Takara Bio

Curio Bioscience
Rubicon Genomics
WaferGen Biosystems
Description
Curio Bioscience is a biotechnology firm offering tools and applications for research in cancer biology, developmental biology, immunology, and neuroscience.
Rubicon Genomics is a biotechnology company specializing in pre-analytical amplification technologies for human genetics applications. Located in Ann Arbor, Michigan, it supplies products to research and commercial markets through direct sales and distributors, enabling sample processing beyond traditional limits in clinical and diagnostic workflows.
WaferGen Biosystems is a Fremont-based genomic analysis company offering the SmartChip Real-Time PCR System. This platform enables high-throughput microRNA and mRNA gene expression profiling plus SNP genotyping, supporting biomarker validation in research and diagnostics.
HQ CountryUnited StatesUnited StatesUnited States
HQ City
San Francisco, CA
Ann Arbor, MI
San Francisco, CA
Deal Date15 Jan 202515 Dec 201613 May 2016
Valuation$6B$75M$50M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Takara Bio acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Takara Bio

When was Takara Bio founded?Takara Bio was founded in 2002.
Where is Takara Bio headquartered?Takara Bio is headquartered in Japan.
How many employees does Takara Bio have?As of today, Takara Bio has over 1K employees.
Who is the CEO of Takara Bio?Takara Bio's CEO is Koichi Nakao.
Is Takara Bio publicly listed?Yes, Takara Bio is a public company listed on Tokyo Stock Exchange.
What is the stock symbol of Takara Bio?Takara Bio trades under 4974 ticker.
When did Takara Bio go public?Takara Bio went public in 2004.
Who are competitors of Takara Bio?Takara Bio main competitors include Anhui Huaheng, Biotest, CryoPort, SEEGENE, SunOpta, Absci, Gujarat State Fertilizers, Bide Pharmatech Co, Grupa Azoty, Suzhou Sepax Technologies.
What is the current market cap of Takara Bio?Takara Bio's current market cap is $864M.
What is the current revenue of Takara Bio?Takara Bio's last 12 months revenue is $255M.
What is the current revenue growth of Takara Bio?Takara Bio revenue growth (vs. last FY) is (10%).
What is the current EV/Revenue multiple of Takara Bio?Current revenue multiple of Takara Bio is 3.2x.
Is Takara Bio profitable?No, Takara Bio is not profitable.
What is the current net income of Takara Bio?Takara Bio's last 12 months net income is ($61M).
How many companies Takara Bio has acquired to date?As of June 2026, Takara Bio has acquired 3 companies.
What was the largest acquisition by Takara Bio?$6B acquisition of Curio Bioscience on 15th January 2025 was the largest M&A Takara Bio has done to date.
What companies Takara Bio acquired?Takara Bio acquired Curio Bioscience, Rubicon Genomics, and WaferGen Biosystems.
In how many companies Takara Bio has invested to date?Takara Bio hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Takara Bio

Lists including Takara Bio

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial